Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1651

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Progressive Multiple Sclerosis

Interventions

DRUG: BAF312
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals